Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

Events

27 Aug 2016 - 31 Aug 2016

Transapical Technology Facilitates Cardiac Surgery

By HospiMedica International staff writers
Posted on 15 Oct 2013
Print article
Image: The Apica ASC system (Photo courtesy of Apica Cardiovascular).
Image: The Apica ASC system (Photo courtesy of Apica Cardiovascular).
A new surgical platform allows the delivery of aortic and mitral valves through the chest wall and the apex of the beating heart.

The Access, Stabilization, and Closure (ASC) system, in conjunction with minimally invasive surgical (MIS) techniques is used to deliver large-bore therapeutic devices into the beating heart of patients with structural heart disease, via the cardiac apex. The system both seals and stabilizes the tissue of the access site during therapeutic device delivery, minimizing loss of blood from, or induction of air to the beating heart. On completion of the therapeutic treatment, it standardizes apical access and closure, leading to safer heart operations, decreased procedure time, and reduced technical challenges associated with transapical access and closure.

A multicenter clinical trial conducted in Germany of the ASC system demonstrated an excellent safety profile with 100% technical success, superior ease-of-use for surgeons, and reductions in both blood loss and operative time. Follow-up assessments of patients showed that the system provided robust closure, with no postoperative apical bleeding complications and no degradation of left ventricular function. The ASC system is a product of Apica Cardiovascular (Galway, Ireland), and has received the European community CE marking of approval.

“Clinically, the Apica ASC System is easy to use, standardizing apical access and closure. Its ‘sutureless’ access coil minimizes both rib spreading and patient pain, providing a dry access site with no peri-sheath bleeding,” said Prof. Thomas Walther, MD, of the Kerckhoff Klinik (Hamburg, Germany), who participated in the device’s clinical study. “Apical closure was reliable, rapid, and completely dry, demonstrating a reduction in operative times, blood loss, use of blood products and apical access site complications.”

“Apica has provided an excellent example of how a new medical device, which was initially conceived and developed overseas, could be brought to Ireland and developed here so that it can be made available for export to treat patients globally,” said James Greene, CEO of Apica Cardiovascular.

The transapical transcatheter aortic valve implantation (TAVI) approach is used for patients whose arteries are too small or too diseased for the transfemoral approach. The delivery system is designed for replacement valve implantation via the apex of the heart, which is reached through a small incision made between the ribs just below the left nipple. It is then expanded using a balloon to fit across the stenotic aortic valve, holding it open permanently.

Related Links:

Apica Cardiovascular



Print article
ARAB HEALTH
JD Honigberg International

Channels

Women's Health

view channel
Image: A new study describes a novel index that quantifies net bone formation and resorption, which may help identify women that experience fast bone loss across the menopause transition (Photo courtesy of UCLA).

Novel Index Could Identify Rapid Bone Loss Risk

Developed by researchers at the University of California, Los Angeles (UCLA; USA), and the University of Tokyo (Japan), the Bone Balance Index (BBI) estimates the relationship between resorption (urinary... Read more

Business

view channel

GE and ThoughtWire Partner to Improve Digital Transformation in Healthcare

GE Healthcare Partners (Little Chalfont, UK) and ThoughtWire (Ontario, Canada) have entered into a five-year collaboration agreement to help hospitals and health systems implement new digital tools for improving their productivity, quality of care and overall patient experience. Both GE Healthcare Partners and the Toronto-based... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.